Form 8-K - Current report:
SEC Accession No. 0001628280-23-017872
Filing Date
2023-05-12
Accepted
2023-05-12 16:02:42
Documents
13
Period of Report
2023-05-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20230511.htm   iXBRL 8-K 74302
2 EX-10.1 exhibit101-2013employeesto.htm EX-10.1 135728
  Complete submission text file 0001628280-23-017872.txt   365796

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20230511.xsd EX-101.SCH 1897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20230511_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20230511_pre.xml EX-101.PRE 12508
7 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20230511_htm.xml XML 10554
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 23915474
SIC: 2834 Pharmaceutical Preparations